Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Toine Pieters
 -- 1660 2023-10-25 07:56:09 |
2 references update
Fanny Huang
 Meta information modification 1660 2023-10-26 07:47:10 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Oosten, W.; Vos, E.; Los, L.; Nelwan, M.; Pieters, T. Cannabis as Drug. Encyclopedia. Available online: https://encyclopedia.pub/entry/50769 (accessed on 01 August 2024).
Oosten W, Vos E, Los L, Nelwan M, Pieters T. Cannabis as Drug. Encyclopedia. Available at: https://encyclopedia.pub/entry/50769. Accessed August 01, 2024.
Oosten, Wesley, Elena Vos, Leontien Los, Michel Nelwan, Toine Pieters. "Cannabis as Drug" Encyclopedia, https://encyclopedia.pub/entry/50769 (accessed August 01, 2024).
Oosten, W., Vos, E., Los, L., Nelwan, M., & Pieters, T. (2023, October 25). Cannabis as Drug. In Encyclopedia. https://encyclopedia.pub/entry/50769
Oosten, Wesley, et al. "Cannabis as Drug." Encyclopedia. Web. 25 October, 2023.
Cannabis as Drug
Edit
This entry is adapted from the peer-reviewed paper 10.3390/psychoactives2040019

Various effects of cannabis have been reported, some of which are positive and some negative. Cannabis is one of the most popular drugs of the 21st century, especially among adolescents and young adults. Research shows that cannabis may have positive effects on symptoms associated with neurological disorders, such as multiple sclerosis (MS) and chronic pain.  For example, cannabis-based medication can improve subjective alleviation of MS symptoms and improve appetite and sleep. As the brain continues to develop throughout adolescence, cannabis may influence neuropsychological development and functioning.

adolescence drug cannabis

1. Mechanism of Action

While consisting of more than 400 different active constituents, the cannabinoid Δ9-tetrahydrocannabinol (THC) is the primary psychoactive constituent of the Cannabis sativa plant. THC is believed to be primarily responsible for the addictive potential and cognitive effects of cannabis [1]. Another major cannabinoid in cannabis is cannabidiol (CBD), which is a potent anti-inflammatory agent that causes a variety of other effects [2][3].
The neurobiological mechanism underlying the effects of cannabis is the endogenous cannabinoid system or endocannabinoid system (ECS). The ECS has a regulatory role in neurotransmitter release. The two main receptors of this system are the cannabinoid CB1 and cannabinoid CB2 receptors. The CB1 receptor is a pre-synaptic heteroreceptor that can primarily be found in the central nervous system and is abundant in brain areas associated with emotional responses, motivation, and motor control. The CB2 receptor is primarily located in the peripheral and immune tissues. Both receptors may be activated by either endocannabinoids (naturally generated inside the body) or cannabis and cannabis-related synthetic compounds [3]. The neuronal activity of other transmitter systems, such as the glutamatergic, dopaminergic, and GABAergic system, can be modulated by the ECS. The ECS is a retrograde messenger system that regulates both inhibitory and excitatory neurotransmission according to an on-demand principle [2]. It has been implicated in a wide variety of behavioral functions such as various cognitive functions, the regulation of fear and anxiety-related behavior, and the modulation of the effects of drugs of abuse [4][5]. Moreover, the ECS is considered to play an important role in higher-order brain functions, including executive function, which continue to develop during adolescence [4][6].
THC exhibits partial agonistic activity for both CB1 and CB2 receptors [7]. It has been shown that THC administration can disrupt the endocannabinoid-mediated regulation of synaptic transmission [8]. CBD has low affinity for both CB1 and CB2 receptors and is a negative allosteric modulator that reduces the binding of CB1 agonists. CBD has been shown to have beneficial neuroprotective, anxiolytic, antipsychotic, and anti-inflammatory properties, though the underlying mechanisms for these effects remain elusive [9]. Many of the psychological effects of cannabis are biphasic, thus depending on the dose level, the THC/CBD ratio, and the user. Due to these biphasic effects, cannabis can either lead to relaxation and euphoria or anxiety and dysphoria. Anxiety due to cannabis use appears to be related to the THC level of the dose as well as the anxiolytic action of CBD. A high dose of CBD combined with THC reduces the intoxicating effects of THC [10].
Importantly, the ECS reaches peak activity and expression during adolescence and is involved in fine-tuning the mesolimbic dopamine pathway, which is involved in regulating reward-associated processes [2]. This makes the ECS a key modulator of adolescent developmental processes involving the mesolimbic reward circuitry and, subsequently, a key modulator in vulnerability to drug addiction. THC leads to elevated dopamine levels in the mesolimbic dopamine system [2]. Therefore, it is possible that the use of cannabis during adolescence can disrupt normal brain development and increase vulnerability to drug addiction [11].

2. Effects of Cannabis Use

Various effects of cannabis have been reported, some of which are positive and some negative. Research shows that cannabis may have positive effects on symptoms associated with neurological disorders, such as multiple sclerosis (MS) and chronic pain [12]. For example, cannabis-based medication can improve subjective alleviation of MS symptoms and improve appetite and sleep [12][13]. Moreover, research among 274 participants with an average age of 51.2 years with treatment-resistant chronic pain showed that medicinal cannabis improved pain symptom scores, pain severity scores, and pain interference scores. In addition, social and emotional disability scores improved and opioid consumption decreased [14]. Cannabis is also used to treat sleep disorders. However, whereas cannabis improves sleep in patients with pain-related disorders, there is no benefit for healthy participants’ sleep. While participants report subjective improvements in sleep, there are no objective improvements found in sleep patterns [15]. In short, evidence shows that cannabis might be of therapeutic value. 
Besides promising therapeutic effects, adverse effects of cannabis use have been reported. A distinction can be made between adverse effects observed in short-term use versus those observed in long-term or heavy cannabis use. The adverse effects of short-term use include impaired short-term memory and motor coordination [16], altered judgement [17], hallucinations, and paranoia [18][19]. These effects can interfere with learning and retaining information and increase the risk of injuries by interfering with driving abilities [17][20]. Adverse effects of long-term or heavy use include altered brain development, cognitive impairment, poor educational outcomes, increased risk of psychosis [21], and diminished life satisfaction and achievement [18]. Individuals who use cannabis have a one in five risk of developing CUD [22]. Moreover, Blanco et al. (2016) showed that individuals who used cannabis in the last twelve months had a higher chance of developing any mood, anxiety, and/or SU disorder than individuals who did not use cannabis [23].
Importantly, the adverse effects of cannabis are influenced by the age of cannabis use onset, the maximum daily use in terms of dosage, and the conditions of use [21][24]. Most of the effects of long-term/heavy use named above are strongly associated with cannabis use that begins early in adolescence. In addition, early and regular cannabis use is a predictor for increased risk of CUD. Individuals who begin to use cannabis in adolescence are approximately 2–4 times more likely to have symptoms of cannabis dependence within the first two years of use than those who begin use in adulthood [25]. Likewise, altered brain development, cognitive impairment, poor educational outcomes, and diminished life satisfaction and achievement are all related to early initial use [18]. Another factor that plays an important role in the eventual effect of using is the potency of cannabis. For example, the average THC level of Dutch home-grown cannabis (Nederwiet) is significantly higher than that of imported cannabis [26]. Compared with low-potency cannabis, high-potency cannabis appears to be associated with a greater risk of anxiety, depression, psychotic symptoms, and cannabis dependence [27].
In short, besides therapeutic effects, cannabis can have serious adverse effects. Adolescents and young adults need to take special caution when using high (THC)-potency cannabis products and be aware of the additional risks of starting cannabis use at an early age of onset on a regular basis and with a family history of mental health problems.

3. Neuropsychological Effects of Cannabis Use

As the brain continues to develop throughout adolescence, cannabis may influence neuropsychological development and functioning. In view of the increased sensitivity of the cannabinoid system and the ongoing maturation of particularly the frontal regions of the brain during adolescence, exogenous cannabinoids could disrupt normal brain development and have an impact on cognitive function [28]. Indeed, several animal and human studies have provided evidence for the association between cannabis exposure during adolescence and connectivity and morphological changes in brain structures that are densely populated with cannabinoid receptors (e.g., in the hippocampus, cerebellum and prefrontal cortex (PFC)) [29][30]. Weiland et al. (2015), however, found no association between daily cannabis use and morphological changes in brain structures in adolescents [31]. Although research into the relationship between cannabis use and morphological/structural changes is inconclusive, various studies have shown that long-term and heavy cannabis use is associated with impaired neurocognitive functioning in animals and humans [32][33][34]. For example, studies comparing adolescents using cannabis on a regular basis with a control group reported that they performed more poorly on tasks assessing verbal memory [35][36], intelligence [37], attention [35][36], and executive functions [36][37][38] and that they have a reduced processing speed [36][38]. However, these results should be treated with caution as it is not entirely clear how and to what extent cannabis affects mental functions. For example, THC seems to interfere with the encoding of verbal memory without interfering with retrieval, suggesting that cannabis does not influence learned information prior to the use [39]. Moreover, there is no consensus about the way cannabis use and impaired executive functions (EFs) are related. One mechanism by which poorly developed EFs may increase the risk of cannabis use is through more impulsive risk-taking and externalizing behavior, which is associated with substance use. Gustavson et al. (2017) found that impaired EFs were indeed a risk factor for early aspects of (poly)substance use in adolescence. However, non-EF factors, such as genetic factors that influence the subjective effects of substances, play a larger role in the actual progression to substance dependence [40].
Whether or not the neuropsychological effects of cannabis persist after extended periods of abstinence is still debated. Some studies have reported (subtle) lasting neuropsychological deficits in adolescent cannabis users compared to non-users [36][41]. For example, overactive brain regions involved in higher-order cognitive processes [42] and the default mode network—a set of regions in the brain that are active during passive tasks and possibly involved in the capacity to imagine future actions or events [43]—were seen in cannabis users compared to a control group after a period of abstinence [42]. These results indicate a vulnerability of the adolescent brain to residual effects of long-term cannabis use [11]. However, meta-analyses have shown that no residual, non-acute effects of cannabis use on cognitive performance in adolescents and adults were detectable after one month or more of abstinence [44][45]. Factors that affect the impact of cannabis use are the magnitude and frequency of use, medical versus recreational use, and the length of abstinence [46].
An important limitation is that most studies contributing to this debate are retrospective or cross-sectional case–control, without proper assessment of cognitive function prior to the onset of cannabis use. To clarify temporal associations between neurocognitive development and cannabis use and guide prevention efforts, prospective longitudinal studies are needed that include pre- and post-drug use neurocognitive assessments [28].

References

  1. Crean, R.D.; Crane, N.A.; Mason, B.J. An evidence based review of acute and long term effects of cannabis use on executive cognitive functions. J. Addict. Med. 2011, 5, 1.
  2. Mechoulam, R.; Parker, L.A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 2013, 64, 21–47.
  3. Peng, J.; Fan, M.; An, C.; Ni, F.; Huang, W.; Luo, J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin. Pharmacol. Toxicol. 2022, 130, 439–456.
  4. Pattij, T.; Wiskerke, J.; Schoffelmeer, A.N. Cannabinoid modulation of executive functions. Eur. J. Pharmacol. 2008, 585, 458–463.
  5. Ruehle, S.; Rey, A.A.; Remmers, F.; Lutz, B. The endocannabinoid system in anxiety, fear memory and habituation. J. Psychopharmacol. 2011, 26, 23–39.
  6. Caballero, A.; Granberg, R.; Tseng, K.Y. Mechanisms contributing to prefrontal cortex maturation during adolescence. Neurosci. Biobehav. Rev. 2016, 70, 4–12.
  7. Reggio, P.H. Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Curr. Med. Chem. 2010, 17, 1468–1486.
  8. Oomen, P.P.; van Hell, H.H.; Bossong, M.G. The acute effects of cannabis on human executive function. Behav. Pharmacol. 2018, 29, 605–616.
  9. Morales, P.; Reggio, P.H.; Jagerovic, N. An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front. Pharmacol. 2017, 8, 422.
  10. Solowij, N.; Broyd, S.J.; Greenwood, L.; Van Hell, H.; Martelozzo, D.; Rueb, K.; Todd, J.; Liu, Z.; Galettis, P.; Martin, J.H.; et al. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects. Eur. Arch. Psychiatry Clin. Neurosci. 2019, 269, 17–35.
  11. Hurd, Y.L.; Manzoni, O.J.; Pletnikov, M.V.; Lee, F.S.; Bhattacharyya, S.; Melis, M. Cannabis and the developing brain: Insights into its long-lasting effects. J. Neurosci. 2019, 39, 8250–8258.
  12. Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; et al. Cannabinoids for Medical Use. JAMA 2015, 313, 2456.
  13. Chohan, H.; Greenfield, A.L.; Yadav, V.; Graves, J. Use of Cannabinoids for Spasticity and Pain Management in MS. Curr. Treat. Options Neurol. 2015, 18, 1.
  14. Haroutounian, S.; Ratz, Y.; Ginosar, Y.; Furmanov, K.; Saifi, F.; Meidan, R.; Davidson, E. The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain. Clin. J. Pain 2016, 32, 1036–1043.
  15. Velzeboer, R.; Malas, A.; Boerkoel, P.; Cullen, K.; Hawkins, M.; Roesler, J.; Lai, W.W.K. Cannabis dosing and administration for sleep: A systematic review. Sleep 2022, 45, zsac218.
  16. Weinstein, A.; Livny, A.; Weizman, A. Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users. Curr. Pharm. Des. 2017, 22, 6366–6379.
  17. Hartman, R.L.; Huestis, M.A. Cannabis Effects on Driving Skills. Clin. Chem. 2013, 59, 478–492.
  18. Volkow, N.D.; Baler, R.D.; Compton, W.M.; Weiss, S.R. Adverse health effects of marijuana use. N. Engl. J. Med. 2014, 370, 2219–2227.
  19. Morrison, P.D.; Zois, V.; McKeown, D.A.; Lee, T.D.; Holt, D.W.; Powell, J.F.; Kapur, S.; Murray, R.M. The acute effects of synthetic intravenous Δ9 tetrahydrocannabinol on psychosis, mood, and cognitive functioning. Psychol. Med. 2009, 39, 1607.
  20. Sewell, R.A.; Poling, J.; Sofuoglu, M. The Effect of Cannabis Compared with Alcohol on Driving. Am. J. Addict. 2009, 18, 185–193.
  21. Murray, R.M.; Quigley, H.; Quattrone, D.; Englund, A.; Di Forti, M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: Increasing risk for psychosis. World Psychiatry 2016, 15, 195–204.
  22. Leung, J.; Chan, G.C.; Hides, L.; Hall, W.D. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addict. Behav. 2020, 109, 106479.
  23. Blanco, C.; Hasin, D.S.; Wall, M.M.; Flórez-Salamanca, L.; Hoertel, N.; Wang, S.; Kerridge, B.T.; Olfson, M. Cannabis Use and Risk of Psychiatric Disorders. JAMA Psychiatry 2016, 73, 388.
  24. Hooper, S.R.; Woolley, D.; De Bellis, M.D. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology 2014, 231, 1467–1477.
  25. Chen, C.; Storr, C.L.; Anthony, J.C. Early-onset drug use and risk for drug dependence problems. Addict. Behav. 2009, 34, 319–322.
  26. Pijlman, F.T.A.; Rigter, S.M.; Hoek, J.; Goldschmidt, H.M.J.; Niesink, R.J.M. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict. Biol. 2005, 10, 171–180.
  27. Wilson, J.; Freeman, T.P.; Mackie, C.J. Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc. Health 2019, 3, 121–128.
  28. Castellanos-Ryan, N.; Pingault, J.B.; Parent, S.; Vitaro, F.; Tremblay, R.E.; Seguin, J.R. Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Dev. Psychopathol. 2017, 29, 1253.
  29. Rubino, T.; Prini, P.; Piscitelli, F.; Zamberletti, E.; Trusel, M.; Melis, M.; Parolaro, D. Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol. Dis. 2015, 73, 60–69.
  30. Burns, H.D.; Van Laere, K.; Sanabria-Bohórquez, S.; Hamill, T.G.; Bormans, G.; Eng, W.S.; Krause, S. MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. USA 2007, 104, 9800–9805.
  31. Weiland, B.J.; Thayer, R.E.; Depue, B.E.; Sabbineni, A.; Bryan, A.D.; Hutchison, K.E. Daily Marijuana Use Is Not Associated with Brain Morphometric Measures in Adolescents or Adults. J. Neurosci. 2015, 35, 1505–1512.
  32. Fried, P.A.; Watkinson, B.; Gray, R. Neurocognitive consequences of marihuana—A comparison with pre-drug performance. Neurotoxicol. Teratol. 2005, 27, 231–239.
  33. Rubino, T.; Parolaro, D. The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol. Psychiatry 2016, 79, 578–585.
  34. Lubman, D.I.; Cheetham, A.; Yücel, M. Cannabis and adolescent brain development. Pharmacol. Ther. 2015, 148, 1–16.
  35. Hanson, K.L.; Winward, J.L.; Schweinsburg, A.D.; Medina, K.L.; Brown, S.A.; Tapert, S.F. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict. Behav. 2010, 35, 970–976.
  36. Medina, K.L.; Hanson, K.L.; Schweinsburg, A.D.; Cohen-Zion, M.; Nagel, B.J.; Tapert, S.F. Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J. Int. Neuropsychol. Soc. JINS 2007, 13, 807.
  37. Harvey, M.A.; Sellman, J.D.; Porter, R.J.; Frampton, C.M. The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev. 2007, 26, 309–319.
  38. Lisdahl, K.M.; Price, J.S. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J. Int. Neuropsychol. Soc. JINS 2012, 18, 678.
  39. Ranganathan, M.; Radhakrishnan, R.; Addy, P.H.; Schnakenberg-Martin, A.M.; Williams, H.; Carbuto, M.; Elander, J.; Pittman, B.; Andrew Sewell, R.; Skosnik, P.D.; et al. Tetrahydrocannabinol (THC) impairs encoding but notretrieval of verbal information. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2017, 79, 176–183.
  40. Gustavson, D.E.; Stallings, M.C.; Corley, R.P.; Miyake, A.; Hewitt, J.K.; Friedman, N.P. Executive functions and substance use: Relations in late adolescence and early adulthood. J. Abnorm. Psychol. 2017, 126, 257.
  41. Broyd, S.J.; van Hell, H.H.; Beale, C.; Yuecel, M.; Solowij, N. Acute and chronic effects of cannabinoids on human cognition—A systematic review. Biol. Psychiatry 2016, 79, 557–567.
  42. Jager, G.; Block, R.I.; Luijten, M.; Ramsey, N.F. Cannabis use and memory brain function in adolescent boys: A cross-sectional multicenter functional magnetic resonance imaging study. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49, 561–572.
  43. Buckner, R.L.; Andrews-Hanna, J.R.; Schacter, D.L. The brain’s default network: Anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124, 1–38.
  44. Schreiner, A.M.; Dunn, M.E. Residual effects of cannabis use on neurocognitiveperformance after prolonged abstinence: A meta-analysis. Exp. Clin. Psychopharmacol. 2012, 20, 420.
  45. Schulte, M.H.; Cousijn, J.; den Uyl, T.E.; Goudriaan, A.E.; van den Brink, W.; Veltman, D.J.; Wiers, R.W. Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. Clin. Psychol. Rev. 2014, 34, 531–550.
  46. Sagar, K.A.; Gruber, S.A. Interactions between recreational cannabis use and cognitive function: Lessons from functional magnetic resonance imaging. Ann. N. Y. Acad. Sci. 2019, 1451, 42.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Substance Abuse
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Wesley Oosten
,
Elena Vos
,
Leontien Los
,
Michel Nelwan
,
Toine Pieters
View Times: 205
Revisions: 2 times (View History)
Update Date: 26 Oct 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback